Trial Profile
Granulocyte colony stimulating factor (G-CSF) to treat acute-on-chronic liver failure: A multicentre randomized Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Filgrastim (Primary)
- Indications Liver failure
- Focus Therapeutic Use
- Acronyms GRAFT
- 05 Aug 2021 Primary endpoint (Transplant-free survival at 90 days, defined as time from randomization to death or OLT, censoring patients alive without OLT at the date of last information.) has not been met. according to the results published in the Journal of Hepatology.
- 05 Aug 2021 Results published in the Journal of Hepatology
- 13 Jul 2020 Status changed from active, no longer recruiting to completed.